Biotech Stocks Hit Post-Pandemic High on Moderna-Merck Cancer Vaccine Success

Key Facts

In a move reflecting the rapid evolution of medical innovation, Moderna and Merck have achieved significant success in Phase 3 trials for a personalized melanoma vaccine. According to reports, biotech sector stocks reached their highest levels since the post-pandemic period following these positive results. This breakthrough has bolstered investor confidence in the broader application of mRNA technology beyond its initial use for COVID-19.

Regarding the performance of related companies, market data showed a positive reaction within the healthcare sector. Per market data, Merck (MRK) shares closed at $135.18 (close of August 18, 2026), after reaching an intraday high of $137.98. Similarly, Merck's German-listed shares (6MK.DE) saw active trading, closing at €128.38 (close of August 19, 2026) after hitting a session high of €130.16.

Traders are currently monitoring the sustainability of this momentum in the biotech sector as MRK stabilizes at its current levels. Looking at the economic calendar, there are no immediate catalysts for the sector in the coming days; however, markets await global inflation and growth data to assess risk appetite for growth stocks, noting that UK GDP grew by 1.2% annually as of August 13, 2026.